이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Celltrion to expand production capacity to 310,000 liters by 2019
- Collected
- 2016.05.26
- Distributed
- 2016.05.27
- Source
- Go Direct
The company will double the capacity of its first plant by 2018 and build a third plant that will have a 120,000-liter capacity by 2019. The new facilities will enter commercial operations in 2019 and 2021, respectively.
The company said its capacity expansion is needed to keep up with the growth in global demand for Remsima, cheaper version of Johnson & Johnson’s blockbuster Remicade to treat rheumatoid arthritis and the future launch of follow-up biosimilars such as Truxima and Herzuma. Remsima was recently approved in the U.S. amid upbeat sales in Europe. Remsima was also approved for the treatment of patients with ulcerative colitis in Canada.
With capacity expansion, Celltrion will beat rival contract manufacturing organizations -- Germany’s Boehringer Ingelheim (300,000 liters) and Switzerland’s Lonza (280,000 liters). Samsung Biologics Co., another Korean producer of biologic drugs, has a plan to increase its annual production capacity to 360,000 liters by 2018.
By Shin Chan-ok and Lee Dong-in
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]